^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Bladder Cancer
    Drug:Opdivo (nivolumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Published date:
    10/20/2021
    Excerpt:
    Bladder cancer: Adjuvant therapy...Other recommended regimens...Nivolumab
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    ASCO 2022
    Title:

    Results for patients with muscle-invasive bladder cancer (MIBC) in the CheckMate 274 trial.

    Published date:
    05/26/2022
    Excerpt:
    CheckMate 274 is a phase 3, randomized, double-blind trial of adjuvant NIVO vs PBO in high-risk muscle-invasive urothelial carcinoma...Of 709 randomized pts in the trial, 560 had MIBC (NIVO, n = 279; PBO, n = 281). With a minimum follow-up of 11.0 months, a DFS benefit was observed with NIVO vs PBO in these pts, regardless of tumor PD-L1 expression...Improvement in DFS was observed with NIVO over PBO in pts with MIBC after radical resection regardless of tumor PD-L1 expression.
    Secondary therapy:
    Chemotherapy
    DOI:
    10.1200/JCO.2022.40.16_suppl.4585
    Trial ID:
    CheckMate 274